Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma-Reference-Cited by-同舟云学术

Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma

Published:2017-11-02 Issue:1 Volume:31 Page:110-114
ISSN:1755-1471
Container-title:Pigment Cell & Melanoma Research
language:en
Short-container-title:Pigment Cell Melanoma Res.

Author:

Algazi Alain P.¹^ORCID,Esteve-Puig Rosaura²,Nosrati Adi²,Hinds Brian³,Hobbs-Muthukumar Adele¹,Nandoskar Prachi¹,Ortiz-Urda Susana²,Chapman Paul B.⁴,Daud Adil¹

Affiliation:

1. UCSF Melanoma Oncology; San Francisco CA USA

2. UCSF Dermatology; San Francisco CA USA

3. UCSD Dermatopathology; La Jolla CA USA

4. Memorial Sloan Kettering Cancer Center; New York NY USA

Funder

National Comprehensive Cancer Network

Publisher

Wiley

Subject

Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pcmr.12644/fullpdf

Reference18 articles.

1. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies;Algazi;Cancer,2016

2. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: A non-randomised, open-label phase 2 study;Ascierto;The Lancet. Oncology,2013

3. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors;Bedard;Clinical Cancer Research: An Official Journal of the American Association for Cancer Research,2015

4. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial;Carvajal;JAMA,2014

5. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma;Colombino;Journal of Clinical Oncology: An Official Journal of the American Society of Clinical Oncology,2012

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors;Translational Oncology;2024-09

2. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma;American Journal of Clinical Dermatology;2024-02-08

3. BRAF — a tumour-agnostic drug target with lineage-specific dependencies;Nature Reviews Clinical Oncology;2024-01-26

4. A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers;Cancer;2024-01-23

5. Treatment for Stage IV;Melanoma;2024